-If Approved Teplizumab will be the First Disease-Modifying Therapy for Type 1 Diabetes - Certain statements in this press release are forward-looking, including but not limited to, statements ...

Sanofi proposed to acquire Provention Bio for $2.9 billion in cash at a 273% premium over the previous closing price (before the deal announcement). The acquisition is expected to be a net positive ...

RED BANK, N.J., January 6, 2023 /PRNewswire/ -- Provention Bio, Inc. (PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today ...

The U.S. antitrust watchdog is taking more time to review the proposed combination of Sanofi and Provention Bio, two diabetes drug developers. Meanwhile, all eyes in biopharma are on the merger ...

Sanofi understandably likes the idea of adding Provention's Tzield product to its lineup. The drug won U.S. regulatory approval in 2022 to delay the onset of stage 3 type 1 diabetes (T1D) in adults, ...

OLDWICK, N.J., May 20, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today ...

Sanofi’s SNY announced acquisition of Provention Bio adds new diabetes drug Tzield to Sanofi’s entrenched cardiometabolic platform. However, we don’t see the nearly $3 billion deal as significantly ...

Provention Bio (NASDAQ:PRVB) stock is rocketing higher on Monday following news that Sanofi (NASDAQ:SNY) is acquiring the company. That deal has Sanofi agreeing to acquire Provention Bio for $25 per ...

Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D) Paris and Red Bank, N.J. March 13, 2023 Sanofi and ...

“We are excited to finalize our acquisition of Provention Bio, Inc. This strategic fit for Sanofi lies at the intersection of our growth in immune-mediated diseases and disease-modifying therapies in ...

Sanofi has agreed to buy Provention Bio, a drug developer geared towards intercepting and preventing autoimmune diseases, for $2.9 billion. The deal gives Sanofi access to Provention’s newly-approved ...

Top economic advisers pushed back against criticism that Trump's action could undermine confidence in official U.S. economic data.